This study explores European-style open innovation systems. In the 1980s, major changes were made in European industrial policies, which laid the foundation for current joint research and standardization policies. Having established this foundation, European-style open innovation systems were strengthened after the Lisbon Declaration in 2000. These systems are defined as “joint research projects extending beyond industrial classifications” and “the global expansion of project results through standardization.” This paper examines the Framework Programme, European Technology Platform, and Joint Technology Initiative; it introduces these as systematic mechanisms supporting European-style open innovation systems. In addition, it discusses systems and measures that enable large-scale collaboration among industries, government, and academia and the basis for generating large-scale innovation. In addition, an explanation is provided of the regional and international standardization that acted as a tool for extending these results to European regional markets, and eventually global markets, thus contributing to global competitiveness.

This paper analyzes the pharmaceutical innovation processes behind Takeda Pharmaceutical’s Rozerem and explores relevant success factors. Although much of the previous research deals with the search stage of the upstream innovation process, this paper focuses on downstream clinical trials and regulatory applications (NDA), marketing, and retail stages. Amidst global competition in the development of new medications, this case study reveals management focus on the developmental time period, such as the “parallel research approach,” as the main success factor in Takeda’s development.